Merger of Manus and Inscripta to accelerate biomanufacturing
In Georgia, biomanufacturing firm Manus and life science technology giant Inscripta have announced a strategic merger to establish an end-to-end platform for scalable development, biomanufacturing, and commercialization of bioalternative products. By combining Inscripta’s whole-genome engineering technologies with Manus’ cell factory engineering platform, biomanufacturing expertise, and commercialization capabilities, the merged company is uniquely positioned to deliver […]
